Literature DB >> 15681865

Understanding the role of Leu22 variants in methotrexate resistance: comparison of wild-type and Leu22Arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and NADPH.

Vivian Cody1, Joe R Luft, Walt Pangborn.   

Abstract

Structural data are reported to 2.5 A resolution for the first full analysis of the methotrexate-resistant Leu22Arg (L22R) variant of mouse dihydrofolate reductase (mDHFR) crystallized as a ternary complex with methotrexate (MTX) and the cofactor NADPH. These results are compared with the MTX and NADPH ternary complexes of L22R human DHFR (hDHFR) and those of mouse and human wild-type DHFR enzymes. The conformation of mDHFR Arg22 is such that it makes hydrogen-bonding contacts with Asp21, Trp24 and a structural water molecule, observations which were not made in the L22R hDHFR ternary complex. These data show that there is little difference between the structures of the wild type and L22R variant for either mouse or human DHFR; however, there are significant differences between the species. Comparison of these structures reveals that the active site of mDHFR is larger than that in the hDHFR structure. In mDHFR, the position of MTX is shifted 0.6 A toward helix C (residues 59-65), which in turn is shifted 1.2 A away from the active site relative to that observed in the hDHFR ternary complexes. In the L22R variant mDHFR structure, MTX makes shorter contacts to the conserved residues Ile7, Val115 and Tyr121 than in the L22R variant human DHFR structure. These contacts are comparable in both wild-type enzymes. The unexpected results from this comparison of the mouse and human DHFR complexes bound with the same ligand and cofactor illustrate the importance of detailed study of several species of enzyme, even when there is a high sequence homology between them. These data suggest that the differences in binding interactions of the L22R variant are in agreement with the weaker binding affinity for MTX in the variant enzymes; the larger size of the binding site in mDHFR supports the observation that the binding affinity of MTX for L22R mDHFR is significantly weaker than that of the L22R hDHFR enzyme.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681865     DOI: 10.1107/S0907444904030422

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  40 in total

1.  Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting.

Authors:  Ming-Hsin Li; Seok Ki Choi; Thommey P Thomas; Ankur Desai; Kyung-Hoon Lee; Alina Kotlyar; Mark M Banaszak Holl; James R Baker
Journal:  Eur J Med Chem       Date:  2011-11-23       Impact factor: 6.514

2.  Structural analysis of human dihydrofolate reductase as a binary complex with the potent and selective inhibitor 2,4-diamino-6-{2'-O-(3-carboxypropyl)oxydibenz[b,f]-azepin-5-yl}methylpteridine reveals an unusual binding mode.

Authors:  Vivian Cody; Jim Pace; Jessica Nowak
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-09-08

3.  Structural analysis of Pneumocystis carinii dihydrofolate reductase complexed with NADPH and 2,4-diamino-6-[2-(5-carboxypent-1-yn-1-yl)-5-methoxybenzyl]-5-methylpyrido[2,3-d]pyrimidine.

Authors:  Vivian Cody; Jim Pace; Elizabeth Stewart
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-03-28

4.  Concerted ATP-induced allosteric transitions in GroEL facilitate release of protein substrate domains in an all-or-none manner.

Authors:  Yakov Kipnis; Niv Papo; Gilad Haran; Amnon Horovitz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-21       Impact factor: 11.205

5.  X-ray structure of the ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: a pharmacophore for dual-site inhibitor design.

Authors:  Brad C Bennett; Qun Wan; Md Faiz Ahmad; Paul Langan; Chris G Dealwis
Journal:  J Struct Biol       Date:  2009-05       Impact factor: 2.867

6.  Crystallographic analysis reveals a novel second binding site for trimethoprim in active site double mutants of human dihydrofolate reductase.

Authors:  Vivian Cody; Jim Pace; Jennifer Piraino; Sherry F Queener
Journal:  J Struct Biol       Date:  2011-06-13       Impact factor: 2.867

7.  Structural analysis of Pneumocystis carinii and human DHFR complexes with NADPH and a series of five potent 6-[5'-(ω-carboxyalkoxy)benzyl]pyrido[2,3-d]pyrimidine derivatives.

Authors:  Vivian Cody; Jim Pace
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-12-16

8.  Kinetic and structural characterization of dihydrofolate reductase from Streptococcus pneumoniae.

Authors:  Jeeyeon Lee; Neela H Yennawar; Jongsik Gam; Stephen J Benkovic
Journal:  Biochemistry       Date:  2010-01-12       Impact factor: 3.162

9.  2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.

Authors:  Aleem Gangjee; Hiteshkumar D Jain; Jaclyn Phan; Xin Guo; Sherry F Queener; Roy L Kisliuk
Journal:  Bioorg Med Chem       Date:  2009-12-26       Impact factor: 3.641

10.  Structural analysis of a holoenzyme complex of mouse dihydrofolate reductase with NADPH and a ternary complex with the potent and selective inhibitor 2,4-diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine.

Authors:  Vivian Cody; Jim Pace; Andre Rosowsky
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2008-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.